Rankings
Pricing
Log In
Free Trial
US-listed companies
Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc.
AVTE
Market cap
$56.72M
P/E ratio
Add to your list
Add to your list
Back to summarized table
B
M
K
USD
Annual
Quarterly
Download CSV
Income statement
Balance sheet
Cash flow
Dec 31,
2021
Dec 31,
2022
Net loss
-23
-52
Stock-based compensation expense
2
5
Depreciation and amortization expense
0
0
Accretion of discounts and amortization of premiums on investments, net
0
-1
Prepaid expenses and other current assets
7
-5
Other long-term assets
0
2
Accounts payable
1
1
Accrued and other liabilities
-0
4
Operating lease assets and liabilities, net
-
0
Other liabilities
0
-0
Net cash used in operating activities
-27
-39
Purchases of short-term investments
-
148
Sales and maturities of short-term investments
-
155
Purchases of property and equipment
0
0
Net cash provided by (used in) investing activities
-113
7
Proceeds from sale of Series A redeemable convertible preferred stock, net of issuance costs
64
-
Payments for deferred offering costs
-
0
Proceeds from issuance of common stock under ESPP
-
0
Proceeds from exercise of stock options
-
1
Proceeds from issuance of common stock, net of issuance costs
127
-
Net cash provided by financing activities
190
0
Net (decrease) increase in cash and cash equivalents
50
-32
Right-of-use asset obtained in exchange for operating lease liability
1
1
Deferred offering costs included in accounts payable
-
0
Purchases of property and equipment in accounts payable
0
-